RegenMD - Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells.

RegenMD         Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. January 31, 2011 at 2:03 PM   Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol. 2010 Aug;177(2):547-54 Authors: Nakao N, Nakayama T, Yahata T, Muguruma Y, Saito S, Miyata Y, Yamamoto K, Naoe T Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for reconstituting the hematopoietic microenvironment by improving engraftment in stem cell transplantation. However, the availability of conventional bone marrow (BM)-derived MSCs (BMSCs) is limited. Recent studies showed that a large number of MSCs can be easily isolated from fat tissue (adipose tissue-derived MSCs [ADSCs]). In this study, we extensively evaluated the hematopoiesis-supporting properties of ADSCs, which are largely unknown. In vitro coculture and progenitor assays showed that ADSCs generated significantly more granulocytes and progenitor cells from human hematopoietic stem cells (HSCs) than BMSCs. We found that ADSCs express the chemokine CXCL12, a critical regulator of hematopoiesis, at levels that are three fold higher than those with BMSCs. The addition of a CXCL12 receptor antagonist resulted in a lower yield of granulocytes from ADSC layers, whereas the addition of recombinant CXCL12 to BMSC cocultures promoted the growth of granulocytes. In vivo cell homing assays showed that ADSCs facilitated the homing of mouse HSCs to the BM better than BMSCs. ADSCs injected into the BM cavity of fatally irradiated mice reconstituted hematopoiesis more promptly than BMSCs and subsequently rescued mice that had received a low number of HSCs. Secondary transplantation experiments showed that ADSCs exerted favorable effects on long-term HSCs. These results suggest that ADSCs can be a promising therapeutic alternative to BMSCs. PMID: 20558580 [PubMed - indexed for MEDLINE]         In vivo assessment of acute UVB responses in normal and Xeroderma Pigmentosum (XP-C) skin-humanized mouse models. January 31, 2011 at 2:03 PM   In vivo assessment of acute UVB responses in normal and Xeroderma Pigmentosum (XP-C) skin-humanized mouse models. Am J Pathol. 2010 Aug;177(2):865-72 Authors: García M, Llames S, García E, Meana A, Cuadrado N, Recasens M, Puig S, Nagore E, Illera N, Jorcano JL, Del Rio M, Larcher F In vivo studies of UVB effects on human skin are precluded by ethical and technical arguments on volunteers and inconceivable in cancer-prone patients such as those affected with Xeroderma Pigmentosum (XP). Establishing reliable models to address mechanistic and therapeutic matters thus remains a challenge. Here we have used the skin-humanized mouse system that circumvents most current model constraints. We assessed the UVB radiation effects including the sequential changes after acute exposure with respect to timing, dosage, and the relationship between dose and degree-sort of epidermal alteration. On Caucasian-derived regenerated skins, UVB irradiation (800 J/m(2)) induced DNA damage (cyclobutane pyrimidine dimers) and p53 expression in exposed keratinocytes. Epidermal disorganization was observed at higher doses. In contrast, in African descent-derived regenerated skins, physiological hyperpigmentation prevented tissue alterations and DNA photolesions. The acute UVB effects seen in Caucasian-derived engrafted skins were also blocked by a physical sunscreen, demonstrating the suitability of the system for photoprotection studies. We also report the establishment of a photosensitive model through the transplantation of XP-C patient cells as part of a bioengineered skin. The inability of XP-C engrafted skin to remove DNA damaged cells was confirmed in vivo. Both the normal and XP-C versions of the skin-humanized mice proved proficient models to assess UVB-mediated DNA repair responses and provide a strong platform to test novel therapeutic strategies. PMID: 20558577 [PubMed - indexed for MEDLINE]         Visceral curator: Making art out of living tissue January 31, 2011 at 12:40 PM   I identified tissue engineering as my technology of choice to do that. I approached Professor Miranda Grounds here at the school of anatomy and human ...         In-vivo generation of bone via endochondral ossification by in ... January 31, 2011 at 10:57 AM   The availability of patients'own bone tissue that can be used for these procedures is limited. Thus far bone tissue engineering has not lead to an implant ...         KCI Licenses Wright Medical's GRAFTJACKET® Brand for Wound Care January 31, 2011 at 10:38 AM   "Regenerative medicine plays a significant role in the practice of wound healing, and KCI stands at the forefront of that breakthrough," said Mike Genau, ... See all stories on this topic »         Research and Markets: Tissue Engineering Related Tools and ... January 31, 2011 at 9:37 AM   Government Regulation for the Stem Cell and Tissue Engineering Field 4. US and EU Current & Next Generation Tissue Engineering Materials and Equipment ...         UPDATE 1-Kensey Nash buys pvt medical adhesive maker's assets January 31, 2011 at 8:47 AM   ... the company to further penetrate the regenerative medicine market of soft tissue surgical repair, orthopaedics, sports medicine, spine and neurosurgery. ... See all stories on this topic »         California Stem Cell Agency Already Has Posted Some Statements of Economic Interests January 31, 2011 at 5:34 AM         Researchers Create 3-D Electrospun Nanoscaffold for Human Tissue ... January 31, 2011 at 2:29 AM   ... the University of Alabama at Birmingham's School of Engineering have created a ... tissues such as tendons, muscles and bones during tissue engineering. ... AZoNano.com         XYTOS Reports Cancer Patient Results January 31, 2011 at 1:06 AM   ... introduction of Next Generation Medicine and Medical Procedures in the areas of Stem Cell Therapies, Tissue Engineering, Cellular Medicine, and Cancer. ...         BioTime buys out Cell Targeting January 30, 2011 at 1:34 PM   BioTime Inc. acquires regenerative medicine startup Cell Targeting Inc. in a deal worth about $2.3 million. Stem cell technology developer Cell Targeting ... See all stories on this topic »         South Carolina scientist works to grow meat in lab January 30, 2011 at 9:09 AM   Director of the Advanced Tissue Biofabrication Center in the Department of Regenerative ... Mironov now primarily conducts research on tissue engineering, ...             This email was sent to agupta1213+termsc@gmail.com. Delivered by Feed My Inbox PO Box 682532 Franklin, TN 37068 Account Login Unsubscribe Here